JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

First published online December 12, 2007
J Nucl Med 2007, doi:10.2967/jnumed.106.037200
 © 2007 by Society of Nuclear Medicine
This Article
Right arrow Full Text (Publish Ahead of Print[PDF])
Right arrow All Versions of this Article:
jnumed.106.037200v1
49/1/68    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grant, F. D.
Right arrow Articles by Ted Treves, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grant, F. D.
Right arrow Articles by Ted Treves, S.

Skeletal PET with 18F-Fluoride: Applying New Technology to an Old Tracer

Frederick D. Grant 1, Frederic H. Fahey 1, Alan B. Packard 1, Royal T. Davis 2, Abass Alavi 3, and S. Ted Treves 1*

1 Division of Nuclear Medicine/PET, Children's Hospital Boston, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts
2 Division of Nuclear Medicine/PET, Children's Hospital Boston, Boston, Massachusetts
3 Division of Nuclear Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; University of Pennsylvania Medical School, Philadelphia, Pennsylvania

* To whom correspondence should be addressed. E-mail: ted.treves{at}childrens.harvard.edu.


  Abstract

Although 18F-labeled NaF was the first widely used agent for skeletal scintigraphy, it quickly fell into disuse after the introduction of 99mTc-labeled bone-imaging agents. Recent comparative studies have demonstrated that 18F-fluoride PET is more accurate than 99mTc-diphosphonate SPECT for identifying both malignant and benign lesions of the skeleton. Combining 18F-fluoride PET with other imaging, such as CT, can improve the specificity and overall accuracy of skeletal 18F-fluoride PET and probably will become the routine clinical practice for 18F-fluoride PET. Although 18F-labeled NaF and 99mTc-diphosphonate have a similar patient dosimetry, 18F-fluoride PET offers shorter study times (typically less than 1 h), resulting in a more efficient workflow, improved patient convenience, and faster turnarounds of reports to the referring physicians. With the widespread availability of PET scanners and the improved logistics for the delivery of 18F radiopharmaceuticals, prior limitations to the routine use of 18F-fluoride bone imaging have largely been overcome. The favorable imaging performance and the clinical utility of 18F-fluoride PET, compared with 99mTc-diphosphonate scintigraphy, support the reconsideration of 18F-fluoride as a routine bone-imaging agent.

Key Words: 18F-labeled sodium fluoride, skeletal PET




This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
H. U. Shetty, S. S. Zoghbi, F. G. Simeon, J.-S. Liow, A. K. Brown, P. Kannan, R. B. Innis, and V. W. Pike
Radiodefluorination of 3-Fluoro-5-(2-(2-[18F](fluoromethyl)-thiazol-4-yl)ethynyl)benzonitrile ([18F]SP203), a Radioligand for Imaging Brain Metabotropic Glutamate Subtype-5 Receptors with Positron Emission Tomography, Occurs by Glutathionylation in Rat Brain
J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 727 - 735.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2007 by the Society of Nuclear Medicine.